B+
Bull case
25%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
SEPN
SepternaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.1
Score
AI commentary
Primary-source operating context is constructive around SEP-631, SEP-479, and cash runway [#SEC-8K-2026-05-11], but headline flow is sparse, social coverage is unavailable, and analyst-target breadth is not disclosed. No reliable post-event market-reaction or broad current revision dataset is available; sentiment supports cautious monitoring rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-07-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-23eventSEP-479 Phase 1 dataHigh impact
Septerna initiated the SEP-479 Phase 1 trial in April 2026, with safety, pharmacokinetic, and pharmacodynamic data expected in late 2026 or early 2027 [#SEC-8K-2026-05-11].
2027-07-25eventSEP-631 Phase 2b initiation in CSUHigh impact
Positive Phase 1 data support Phase 2 development, with a chronic spontaneous urticaria Phase 2b trial planned for the second half of 2026 after long-term toxicology completion [#SEC-8K-2026-05-11].
2027-07-25catalystRunway lowers near-term financing overhangHigh impact
The company reported $522.1 million in cash and expects this to support operating plans at least into 2029, reducing near-term financing pressure while clinical programs advance [#SEC-8K-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-25 • Updated nightlySource: Internal modelMethodology